China Isotope & Radiation : VOLUNTARY ANNOUNCEMENT - EXCLUSIVE DISTRIBUTION RIGHT OF XOFIGO IN CHINA GRANTED TO CIRC BY BAYER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA ISOTOPE & RADIATION CORPORATION

中 國 同 輻 股 份 有 限 公 司

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE DISTRIBUTION RIGHT OF XOFIGO®

IN CHINA GRANTED TO CIRC BY BAYER

This announcement is made by China Isotope & Radiation Corporation (the "Company" or "CIRC") on a voluntary basis to inform its shareholders and potential investors of its latest business development.

The board of directors (the "Board") of the Company is pleased to announce that, on 27 August 2020, Xofigo® (Radium [223Ra] Chloride Injection), which was developed by Bayer, was officially approved by the National Medical Products Administration. On 28 August 2020, the Company and Bayer Consumer Care AG ("BAYER") held an internal ceremony to celebrate the successful approval of Xofigo® (Radium [223Ra] Chloride Injection) by the National Medical Products Administration and formally announce an exclusive distribution agreement recently entered into between the Company and BAYER regarding the distribution of Xofigo® in China. Under the agreement, BAYER will grant CIRC the exclusive right to sell the radiopharmaceutical Xofigo® in China, and undertake the import, logistics and sales of Xofigo® across China.

Xofigo® is a novel alpha particle-emitting radioactive therapeutic agent currently approved by more than 50 countries worldwide, including Japan, the United States and the European Union, for the treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases, which can significantly improve the quality of the patients' life.

As a leading enterprise in the nuclear technology application in China, CIRC has rich experience in the import and export of radioactive drug and has strong sales network. CIRC cooperates with BAYER to introduce Xofigo® into Chinese market, which is a meaningful step and represents that CIRC makes an important contribution again in enriching the diagnosis and treatment methods of nuclear medicine, improving the diagnosis and treatment level of nuclear medicine, and promoting applications of nuclear technology in the medical field in China.

Bayer Consumer Care AG is a joint-stock subsidiary of BAYER AG established under Swiss law. Having a history of more than 150 years, BAYER AG is a life science company with core competencies in the life science fields of health care and nutrition. The products and services of the Bayer group are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population.

1

Entering into the exclusive distribution agreement does not constitute a notifiable transaction under Chapter 14 and a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board

China Isotope & Radiation Corporation

Meng Yanbin

Chairman

Beijing, the PRC, 31 August 2020

As at the date of this announcement, the Board comprises Mr. Meng Yanbin, Mr. Wu Jian and Mr. Du Jin as executive Directors; Mr. Zhou Liulai, Mr. Chen Shoulei, Mr. Chen Zongyu, and Ms. Chang Jinyu as non-executive Directors; Mr. Guo Qingliang, Mr. Meng Yan, Mr. Hui Wan Fai and Mr. Tian Jiahe as independent non-executive Directors.

2